Glycogen storage disease (GSD), unspecified, refers to a group of inherited metabolic disorders characterized by the abnormal storage or utilization of glycogen. Glycogen is the primary storage form of glucose in the body, predominantly found in the liver and skeletal muscles. These disorders are caused by deficiencies in specific enzymes involved in the synthesis or breakdown of glycogen. While there are many well-defined types (such as Type I, II, or III), the E74.00 code is used when a patient exhibits clinical and biochemical evidence of a glycogen storage disorder but the specific enzymatic defect or genetic mutation has not yet been identified or specified. These conditions typically manifest as impaired glucose homeostasis, resulting in hypoglycemia during fasting, or as progressive muscle weakness and exercise intolerance, depending on whether the liver or muscle enzymes are primarily affected. Long-term complications can include hepatic adenomas, growth failure, and organomegaly.
Distinguish between unspecified and specified types of Glycogen Storage Disease whenever diagnostic confirmation is available. Use E74.00 only during the initial workup phase before genetic or enzymatic confirmation of specific types like Von Gierke or Pompe disease.
Example: Patient presents with persistent fasting hypoglycemia and massive hepatomegaly. Pending results of G6PC and SLC37A4 genetic sequencing to confirm GSD Type I. Currently documenting as Glycogen storage disease, unspecified, E74.00. Management includes frequent small meals and monitoring of blood glucose levels to prevent metabolic decompensation.
Billing Focus: Documentation of the diagnostic workup phase and the specific symptoms justifying the unspecified code.
Document clinical manifestations such as hepatomegaly, growth retardation, and muscular weakness which support the severity of the unspecified metabolic disorder.
Example: 6-year-old male with Glycogen storage disease, unspecified. Physical exam reveals liver edge 5cm below costal margin (Hepatomegaly R16.0). Growth charts show height at 3rd percentile, consistent with metabolic growth failure. Labs show elevated triglycerides and uric acid. Plan: Initiate uncooked cornstarch therapy 1.5g per kg every 4 hours.
Billing Focus: Inclusion of manifestation codes like R16.0 for hepatomegaly and E88.1 for metabolic syndromes.
Clearly link any secondary complications, such as hyperlipidemia or hyperuricemia, to the primary glycogen storage disorder to facilitate accurate hierarchical coding.
Example: Clinical follow-up for Glycogen storage disease, unspecified (E74.00). Patient is experiencing secondary hyperuricemia (E79.0) requiring Allopurinol and hyperlipidemia (E78.5) managed with dietary restrictions. These are documented as complications of the underlying glycogen metabolism defect.
Billing Focus: Causal linkage statements such as due to or secondary to are essential for coding accuracy.
Record the specific laboratory abnormalities used for monitoring, such as lactate, glucose, and transaminase levels, to justify frequent follow-up visits.
Example: Patient with Glycogen storage disease, unspecified, evaluated for metabolic control. Lab findings: Blood glucose 55 mg/dL (pre-prandial), Lactate 4.2 mmol/L (elevated), AST 120 U/L, ALT 145 U/L. Documentation supports Moderate MDM for a chronic condition with exacerbation risk.
Billing Focus: Laboratory results support the necessity of higher-level E/M services (e.g., 99214).
Incorporate the role of multidisciplinary care, including metabolic genetics and pediatric hepatology, in the patient's long-term management plan.
Example: Care coordination for patient with Glycogen storage disease, unspecified. Patient is followed by Metabolic Genetics for ongoing enzyme activity assays and Pediatric Hepatology for monitoring of hepatic adenoma risk. Current stability achieved via strict adherence to complex carbohydrate diet.
Billing Focus: Documentation of specialist involvement supports the complexity of the case.
Standard for managing GSD patients with laboratory monitoring and dietary adjustments.
Used when a patient with GSD experiences metabolic decompensation or acute illness.
Initial consultation for suspected GSD prior to definitive typing.
Essential for monitoring hypoglycemia in GSD patients.
Monitors liver involvement and potential damage from glycogen storage.
Used to move from E74.00 to a specific subtype code (e.g., testing for G6PC).
Dietary management is the cornerstone of GSD treatment.
Used as a marker for muscle involvement or metabolic stress in GSD.
Used to visualize hepatomegaly and screen for hepatic adenomas.
Monitors iron status, which can be affected by chronic metabolic disorders.